🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Explore Biomarkers Associated With Prognosis of Recurrent and Metastatic CRC After Surgery by Multi-omics Methods

Recruitingn/aAges 18 Years - 99 YearsAllSecond Affiliated Hospital, Zhejiang University, …
NCT05501353 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This project is the first application, which is applied as a single center project and applied according to the screening quantity. This project is a multi-omics approach to explore biomarkers associated with prognosis after secondary radical resection of recurrent and metastatic colorectal cancer. Main research objectives: 1. To detect DNA mutation and methylation in tumor tissues by NGS detection technology (the methylation dimension should be detected in adjacent tissues at the same time), and to explore specific molecular markers related to prognosis; 2. Using NGS test technology of blood in patients with preoperative and postoperative blood ctDNA mutations and methylation double dimension testing, respectively, to explore the preoperative and postoperative ctDNA mutations and the correlation between methylation status and recurrence, including but not limited to predict patients wi

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Colorectal cancer patients with first recurrence and metastasis after previous radical resection 2. Single site/organ metastasis is indicative of reoperation 3. Adenocarcinoma diagnosed by histology or cytology 4. At the time of signing the informed consent, the applicant must be 18 years old or older 5. Life expectancy is at least 12 weeks 6. ECOG score 0\~1 Exclusion Criteria: 1. Currently participating in the intervention study treatment, or receiving other drugs or study devices within 4 weeks before enrollment 2. Concurrent with other malignant tumors 3. The investigator determined that the patient had other serious diseases that might affect follow-up and short-term survival 4. Cardiac function NYHA class III or IV heart disease 5. The presence of definite peripheral nerve disease 6. There is definite hearing loss 7. Other researchers think it is not suitable for inclusion
💊

What it tests

  • no intervention
📍

Where

1 site
the Second Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy